UNICLIN

(Clindamycin)

300mg Capsules

یونی کِلن

(کلنڈامائسن)

۳۰۰ ملی گرام کیپسولز

COMPOSITION:
Each capsule contains:
Clindamycin hydrochloride (B.P) equivalent to Clindamycin . ..... 300 mg
Product complies B.P specs

DESCRIPTION:
Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

THERAPEUTIC INDICATIONS:
UNICLIN has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria; susceptible strains of gram positive aerobic bacteria such as streptococci, staphylococci and pneumococci; & susceptible strains of Chlamydie-trachomatis.
(a) Dental Infections: periodontal abscess and periodontitis.
(b) Bone and Joint Infections.
(c) Skin and soft tissue Infections.
(d) Lower respiratory infections.
(e) Upper respiratory Infections.
(f) Prophylaxis of endocarditis: In patients sensitive /allergic to penicillin(s).

DOSAGE:
600 to 1800 mg/day divided in 2, 3 or 4 equal doses. To avoid the possibility of esophageal irritation, UNICLIN capsules should be taken with a full glass of water.

Dosage in Renal Impairment:
UNICLIN dosage modification is not necessary in patients with renal insufficiency.

Dosage In Hepatic Impairment:
UNICLIN dosage modification is not necessary in patients with hepatic insufficiency.

CONTRAINDICATIONS:
Clindamycin is contraindicated in patients previously found to be sensitive to clindamycin or lincomycin or to any component of the formulation.

SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE:
Pseudomembraneous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider the diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.
Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate-to-severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.

INTERACTION WITH OTHER MEDICAMENTS AND OTHER FORMS OF INTERACTION:
Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patents receiving such agents.

Pregnancy and Lactation:
Clindamycin crosses the placenta in humans and should be used in pregnancy only if clearly needed.

Use in Nursing Mothers:
Clindamycin has been reported to appear in human breast milk in ranges from 0.7 to 3.8 µg/mL.

ADVERSE REACTION:
• Blood and Lymphatic System Disorders
• Hepatobiliary Disorders
• Skin and subcutaneous Tissue Disorders: Maculopapular rash and urticaria have been observed during drug therapy.

STORAGE:
Store below 30ºC in a dry place, protect from light. To be dispensed on the prescription of a registered medical practitioner only. Keep out of the reach of children.

PRESENTATION
UNICLIN 300mg capsules available in blister pack.

- خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
- دوا کو ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر روشنی سے بچا کر خشک جگہ پر رکھیں۔
- صرف رجسٹرڈ ڈاکٹر کے نسخے پر ہی فروخت کریں۔
- بچوں کی پہنچ سے دور رکھیں۔

Manufactured by:
Kaizen Pharmaceuticals (Pvt.) Ltd.
E-127-129, North Western Industrial Zone,
Bin Qasim, Karachi-75020, Pakistan.

ART No. 313